Showing results (181-190 of 253) with videos related to

Sort By:
Pageof 26
The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
American Journal of Hematology|March 5, 2019
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphomaFrancesco Maura, Luca Agnelli, Daniel Leongamornlert, et al.
Haematologica|May 29, 2025
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE studyMartina Magni, Sadhana Jonnalagadda, Francesca Bonifazi, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
Blood Advances|May 5, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE studyGiulia Gabrielli, Beatrice Casadei, Annalisa Chiappella, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.
Pageof 26